MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$358,473,000
EPS
-$3.19
Unit: Dollar

Unit: Dollar
Income Statement
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Revenues
0 0 0 0
Research and development
344,955,000 101,644,000 63,806,000 54,234,000
General and administrative
48,387,000 49,277,000 37,021,000 16,121,000
Total operating expenses
393,342,000 150,921,000 100,827,000 70,355,000
Loss from operations
-393,342,000 -150,921,000 -100,827,000 -70,355,000
Amortization of financing costs
56,000 94,000 88,000 59,000
Interest income, net
33,704,000 40,940,000 15,020,000 1,589,000
Realized loss on investments, net
--0 -42,000
Foreign exchange gain
--0 0
Realized gain on investments, net
55,000 112,000 --
Total other income, net
33,703,000 40,958,000 14,932,000 1,488,000
Net loss
-359,639,000 -109,963,000 -85,895,000 -68,867,000
Unrealized gain (loss) on securities
1,119,000 -173,000 742,000 -295,000
Foreign currency translation loss
---258,000
Foreign currency translation gain (loss)
47,000 -226,000 -29,000 -
Comprehensive loss
-358,473,000 -110,362,000 -85,182,000 -69,420,000
Denominator for basic net loss per share
112,667,000 109,037,000 94,347,000 76,834,000
Denominator for diluted net loss per share
112,667,000 109,037,000 94,347,000 76,834,000
Earnings per share, basic, total
-3.19 -1.01 -0.91 -0.9
Earnings per share, diluted, total
-3.19 -1.01 -0.91 -0.9
Unit: Dollar

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$358,473,000 Foreign currencytranslation gain (loss)$47,000 Unrealized gain (loss) onsecurities$1,119,000 Realized gain oninvestments, net$55,000 Interest income, net$33,704,000 Net loss-$359,639,000 Total other income,net$33,703,000 Amortization of financingcosts$56,000 Loss from operations-$393,342,000 Total operatingexpenses$393,342,000 General andadministrative$48,387,000 Research and development$344,955,000

viking_9_15_logo-svg

Viking Therapeutics, Inc. (VKTX)

viking_9_15_logo-svg

Viking Therapeutics, Inc. (VKTX)